OR WAIT null SECS
Mark Muldowney is head of technology at Sterling Pharma Solutions.
October 15, 2021
New enzymes and protein engineering have advanced biocatalysis processing toward commercial acceptance. Technology and economic roadblocks must be overcome for the process to be widely embraced by pharma.